These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19363607)

  • 1. A comparative study of the effects of bucillamine and salazosulfapyridine in the treatment of rheumatoid arthritis.
    Nakajima M; Ueda N; Ohara H; Abe M; Kinoshita M
    Mod Rheumatol; 2009; 19(4):384-9. PubMed ID: 19363607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment continuation rate in relation to efficacy and toxicity in long-term therapy with low-dose methotrexate, sulfasalazine, and bucillamine in 1,358 Japanese patients with rheumatoid arthritis.
    Nagashima M; Matsuoka T; Saitoh K; Koyama T; Kikuchi O; Yoshino S
    Clin Exp Rheumatol; 2006; 24(3):260-7. PubMed ID: 16870092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA.
    Iwatani M; Inoue E; Nakamura T; Nakajima A; Hara M; Tomatsu T; Kamatani N; Yamanaka H
    Mod Rheumatol; 2006; 16(6):376-80. PubMed ID: 17165000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis patients intolerant to methotrexate.
    Koyama Y; Shiraishi H; Ohta T; Uchino A
    Mod Rheumatol; 2012 Feb; 22(1):100-8. PubMed ID: 21706263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of bucillamine, a D-penicillamine analogue, in patients with active rheumatoid arthritis.
    Sekiguchi N; Kameda H; Amano K; Takeuchi T
    Mod Rheumatol; 2006; 16(2):85-91. PubMed ID: 16633927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ability of disease modifying antirheumatic drugs to induce and maintain improvement in patients with rheumatoid arthritis. epidemiology of DMARDs treatment in Japan.
    Nagashima M; Shu G; Yamamoto K; Yamahatsu S; Yoshino S
    Clin Exp Rheumatol; 2005; 23(1):27-35. PubMed ID: 15789884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of bucillamine as a second-line DMARD in the treatment of rheumatoid arthritis: a retrospective cohort study.
    Suda A; Nagaoka S; Ohono S; Ideguchi H; Soga T; Ishigatsubo Y
    Mod Rheumatol; 2008; 18(6):609-14. PubMed ID: 18682889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicentre trial of bucillamine in the treatment of early rheumatoid arthritis (SNOW study).
    Sagawa A; Fujisaku A; Ohnishi K; Mukai M; Yasuda I; Amasaki Y; Shimizu M; Ichikawa K; Ohsaki H
    Mod Rheumatol; 2011 Jun; 21(3):251-7. PubMed ID: 21188453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan.
    Matsui T; Kuga Y; Kaneko A; Nishino J; Eto Y; Chiba N; Yasuda M; Saisho K; Shimada K; Tohma S
    Ann Rheum Dis; 2007 Sep; 66(9):1221-6. PubMed ID: 17369281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of rheumatoid arthritis following adjunct statin therapy.
    Das S; Mohanty M; Padhan P
    Indian J Pharmacol; 2015; 47(6):605-9. PubMed ID: 26729950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The usefulness of a new triple combination treatment utilizing methotrexate, salazosulfapyridine, and bucillamine in rheumatoid arthritis.
    Matsuno H; Okada M; Sakai Y; Abe C; Katayama K; Sagawa A; Yamasaki K; Kondo M; Funahashi K; Matsubara T
    Mod Rheumatol; 2016; 26(1):51-6. PubMed ID: 26052803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trial.
    Kurasawa T; Nagasawa H; Kishimoto M; Amano K; Takeuchi T; Kameda H
    Mod Rheumatol; 2014 Jul; 24(4):561-6. PubMed ID: 24252035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the disease activity score using the erythrocyte sedimentation rate and C-reactive protein levels in Koreans with rheumatoid arthritis.
    Son KM; Kim SY; Lee SH; Yang CM; Seo YI; Kim HA
    Int J Rheum Dis; 2016 Dec; 19(12):1278-1283. PubMed ID: 26200604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis.
    Wiacek R; Kolossa K; Jankowski T; Jeka S; Karmowski A; Karmowski M; Gworys B
    Adv Clin Exp Med; 2012; 21(3):337-42. PubMed ID: 23214197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-center, retrospective analysis of efficacy and safety of tacrolimus as a second-line DMARD in combination therapy and the risk factors contributing to adverse events in 115 patients with rheumatoid arthritis.
    Ogasawara M; Tamura N; Kageyama M; Onuma S; Kusaoi M; Toyama S; Sekiya F; Matsudaira R; Nawata M; Tada K; Matsushita M; Kempe K; Amano H; Morimoto S; Yamaji K; Takasaki Y
    Clin Rheumatol; 2012 Feb; 31(2):251-7. PubMed ID: 21773713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
    Vermeer M; Kuper HH; Hoekstra M; Haagsma CJ; Posthumus MD; Brus HL; van Riel PL; van de Laar MA
    Arthritis Rheum; 2011 Oct; 63(10):2865-72. PubMed ID: 21647867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort.
    Shu J; Bykerk VP; Boire G; Haraoui B; Hitchon C; Thorne JC; Tin D; Keystone EC; Pope JE;
    J Rheumatol; 2015 Nov; 42(11):2023-8. PubMed ID: 26329342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.
    Svensson B; Boonen A; Albertsson K; van der Heijde D; Keller C; Hafström I
    Arthritis Rheum; 2005 Nov; 52(11):3360-70. PubMed ID: 16255010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term outcome after anti-tumor necrosis factor-alpha therapy in rheumatoid arthritis: do we need to revise our assessment criteria?
    El Miedany Y; Youssef SS; El Gaafary M
    J Rheumatol; 2006 Mar; 33(3):490-7. PubMed ID: 16511918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of handy rheumatoid activity score with 38 joints (HRAS38) in rheumatoid arthritis patients receiving infliximab.
    Kameda H; Sekiguchi N; Nagasawa H; Amano K; Takei H; Suzuki K; Nishi E; Ogawa H; Takeuchi T
    Mod Rheumatol; 2006; 16(6):381-8. PubMed ID: 17165001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.